Format

Send to:

Choose Destination
  • PMID: 22828201 was deleted because it is a duplicate of PMID: 24314888
See comment in PubMed Commons below
Am J Geriatr Psychiatry. 2014 Jan;22(1):34-45. doi: 10.1016/j.jagp.2013.01.019. Epub 2013 Feb 6.

Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.

Author information

  • 1Lilly USA, LLC, Indianapolis, IN.

Abstract

OBJECTIVE:

To compare the efficacy of duloxetine with placebo on depression in elderly patients with major depressive disorder.

DESIGN:

Multicenter, 24-week (12-week short-term and 12-week continuation), randomized, placebo-controlled, double-blind trial.

SETTING:

United States, France, Mexico, Puerto Rico.

PARTICIPANTS:

Age 65 years or more with major depressive disorder diagnosis (one or more previous episode); Mini-Mental State Examination score ≥20; Montgomery-Asberg Depression Rating Scale total score ≥20.

INTERVENTION:

Duloxetine 60 or 120 mg/day or placebo; placebo rescue possible.

MEASUREMENTS:

Primary-Maier subscale of the 17-item Hamilton Depression Rating Scale (HAMD-17) at week 12. Secondary-Geriatric Depression Scale, HAMD-17 total score, cognitive measures, Brief Pain Inventory (BPI), Numeric Rating Scales (NRS) for pain, Clinical Global Impression-Severity scale, Patient Global Impression of Improvement in acute phase and acute plus continuation phase of treatment.

RESULTS:

Compared with placebo, duloxetine did not show significantly greater improvement from baseline on Maier subscale at 12 weeks, but did show significantly greater improvement at weeks 4, 8, 16, and 20. Similar patterns for Geriatric Depression Scale and Clinical Global Impression-Severity scale emerged, with significance also seen at week 24. There was a significant treatment effect for all BPI items and 4 of 6 NRS pain measures in the acute phase, most BPI items and half of the NRS measures in the continuation phase. More duloxetine-treated patients completed the study (63% versus 55%). A significantly higher percentage of duloxetine-treated patients versus placebo discontinued due to adverse event (15.3% versus 5.8%).

CONCLUSIONS:

Although the antidepressant efficacy of duloxetine was not confirmed by the primary outcome, several secondary measures at multiple time points suggested efficacy. Duloxetine had significant and meaningful beneficial effects on pain.

Copyright © 2014 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Duloxetine; elderly depression; pain; symptom severity

PMID:
24314888
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk